Date: 2016-12-12
Type of information: Grant
Company: Herantis Pharma (Finland) TreatER project
Investors: European Commission’s Horizon 2020 programme
Amount: € 6 million
Funding type: grant
Planned used: The EU grant enables extending the clinical study’s CDNF treatment period to 12 months under two separate clinical protocols, and including advanced endpoints such as actigraphy and innovative PET imaging, which are expected to increase the impact of the study. The grant also provides funding for important supportive scientific research at the University of Helsinki and the University of Oxford. Herantis retains full commercial rights to CDNF.
Others: * On December 12, 2016, Herantis Pharma announced that the research and innovation program of the European Union, Horizon 2020, has awarded a grant of approximately €6.0 million for Herantis Pharma Plc’s Phase 1-2 clinical study with Herantis’ drug candidate CDNF for the treatment of Parkinson’s disease, using an innovative drug administration device of Renishaw; and for supporting scientific research. With the grant Herantis expects its financial position to remain positive until the end of 2018 (previously estimated: End of 2017). The short name of the Horizon 2020 project is TreatER. The TreatER project will be executed by a consortium of 11 members including Herantis as the formal sponsor of the clinical study and the owner of CNDF patents, and the University of Helsinki where CDNF was discovered. The consortium also includes three university hospitals responsible for patient treatments: Karolinska University Hospital and Lund University Hospital in Sweden, and Helsinki University Hospital in Finland; two pharmaceutical companies with strong expertise in PD: Lundbeck and Orion Pharma; Karolinska Institutet in Sweden as a leading expert in advanced PET imaging in PD; the University of Oxford and Renishaw plc in the United Kingdom; and the European Parkinson’s Disease Association.
Therapeutic area: CNS diseases - Neurological diseases
